Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Potential Outcomes at 76 patients - wow !

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Nov 14, 2023 2:31pm

160 Views

Post# 35735027

RE:RE:Potential Outcomes at 76 patients - wow !

I agree - especially for a $ 2B USD market.

IMO higher when one considers:

- expanded label use (EDEN, and in actual practice)
- higher per unit price due to higher ARR
- possible use of 3 or 4 columns per patient (proper does in some cases until EA under control)
- use of PMX for other conditions in the future
- worldwide rights to EAA (the critical companion diagnostic)
- iDialco not dead - just shelved until the market can accept home dialysis

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo